Gain Therapeutics, Inc. (NASDAQ:GANX) Receives $8.67 Consensus Price Target from Analysts

Gain Therapeutics, Inc. (NASDAQ:GANX) has earned an average rating of “Moderate Buy” from the seven research firms that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and six have issued a buy rating on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $8.6667.

Several brokerages have recently issued reports on GANX. Roth Capital restated a “buy” rating and issued a $10.00 target price on shares of Gain Therapeutics in a report on Friday, December 19th. HC Wainwright restated a “buy” rating and issued a $8.00 price objective on shares of Gain Therapeutics in a research note on Friday, December 19th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Gain Therapeutics in a report on Monday, December 29th. BTIG Research reissued a “buy” rating and issued a $9.00 target price on shares of Gain Therapeutics in a research report on Wednesday, October 15th. Finally, Maxim Group raised their price target on Gain Therapeutics from $5.00 to $7.00 and gave the stock a “buy” rating in a research note on Tuesday, October 7th.

Institutional Trading of Gain Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Geode Capital Management LLC grew its position in Gain Therapeutics by 2.9% during the 2nd quarter. Geode Capital Management LLC now owns 290,462 shares of the company’s stock worth $523,000 after purchasing an additional 8,251 shares during the last quarter. Marshall Wace LLP grew its holdings in shares of Gain Therapeutics by 41.0% during the second quarter. Marshall Wace LLP now owns 276,433 shares of the company’s stock worth $498,000 after buying an additional 80,407 shares during the last quarter. Wealth Enhancement Advisory Services LLC acquired a new position in Gain Therapeutics in the 3rd quarter valued at about $28,000. Benedict Financial Advisors Inc. increased its position in Gain Therapeutics by 55.6% in the 3rd quarter. Benedict Financial Advisors Inc. now owns 35,000 shares of the company’s stock valued at $62,000 after acquiring an additional 12,500 shares during the period. Finally, JPMorgan Chase & Co. purchased a new stake in Gain Therapeutics during the 3rd quarter valued at approximately $47,000. Hedge funds and other institutional investors own 11.97% of the company’s stock.

Gain Therapeutics Price Performance

Shares of NASDAQ GANX opened at $3.18 on Friday. The stock’s 50-day simple moving average is $2.96 and its 200-day simple moving average is $2.18. The firm has a market capitalization of $122.30 million, a PE ratio of -5.21 and a beta of 0.06. Gain Therapeutics has a fifty-two week low of $1.41 and a fifty-two week high of $4.34. The company has a debt-to-equity ratio of 0.05, a quick ratio of 2.52 and a current ratio of 2.52.

Gain Therapeutics (NASDAQ:GANX) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($0.15) EPS for the quarter, meeting the consensus estimate of ($0.15). As a group, equities research analysts forecast that Gain Therapeutics will post -1 EPS for the current fiscal year.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.